ORYX CEO on research partnerships and cancer vaccine studies

May 10, 2016 Tags: Biotech oncology

Bernard Huber, CEO and founder of ORYX Translational Medicine, and Mike Ward, global director of content for Informa Pharma Intelligence’s insights portfolio, talk about ORYX’s early cancer drug development strategy and partnering models. During BIO-Europe Spring 2016, in Stockholm, Sweden, they discuss how ORYX works with academia, the company’s history in early-stage cancer research and the next steps for its three leading therapeutic vaccines.

Interviewer: Mike Ward – Global Director of Content, Pharma Intelligence, In Vivo/Pink Sheet/Scrip
Interviewee: Bernard Huber – CEO and Founder, ORYX Translational Medicine